Key Takeaways
- • Moderna closed a $1.5 billion five-year non-dilutive credit facility with Ares Management Credit Funds, structured in three tranches to provide capital flexibility through 2028.
- • The facility consists of a $600 million initial term loan funded at closing, a $400 million delayed draw facility available through November 2027, and a $500 million contingent delayed draw facility available through November 2028 (contingent on regulatory milestones in Moderna's clinical pipeline).
- • The non-dilutive debt financing strengthens Moderna's balance sheet without equity dilution, supporting the company's reiterated target of achieving cash breakeven by 2028.
- • Ares Management, a leading global alternative investment manager with healthcare expertise, underwrote the facility, reflecting institutional confidence in Moderna's mRNA platform and commercial pipeline.
- • The financing enhances Moderna's financial flexibility during a pivotal growth phase, with the company maintaining its 2025 financial guidance provided during third-quarter 2025 earnings.
Summary
Moderna announced the closing of a $1.5 billion five-year term loan facility from Ares Management Credit Funds on November 20, 2025, providing non-dilutive capital to strengthen its financial position without shareholder dilution. The facility is structured across three tranches designed to align with the company's funding needs and clinical development timeline through 2028.
The initial tranche of $600 million was funded at closing, providing immediate capital. A second tranche of $400 million is available as a delayed draw term loan facility (DDTL) that Moderna can draw in multiple installments through November 2027 at management's discretion. A third $500 million DDTL tranche is available through November 2028, with draws contingent on Moderna achieving key regulatory milestones tied to its late-stage clinical pipeline, creating performance-based capital access aligned with development progress.
Jamey Mock, Moderna's Chief Financial Officer, stated that while the company remains positioned to achieve its 2028 cash breakeven target, the additional capital "enhances our strong balance sheet and enables increased flexibility over the coming years." The company has reiterated financial guidance provided during its third-quarter 2025 earnings call. Doug Dieter, Co-Head of Ares Specialty Healthcare, emphasized the strategic rationale, noting that "Moderna has already demonstrated the power of its mRNA platform with multiple commercial products and has an impressive and differentiated clinical pipeline."
The facility underscores institutional confidence in Moderna's business model and pipeline maturation. By securing non-dilutive debt rather than equity financing, Moderna preserves shareholder value while extending its runway to cash breakeven. The conditional structure of the third tranche—tied to regulatory achievements—aligns lender interests with clinical execution risk, a common feature in healthcare alternative lending. Legal advisors Goodwin and Proskauer supported the transaction for Moderna and Ares respectively, reflecting the complexity of the credit arrangement.
The initial tranche of $600 million was funded at closing, providing immediate capital. A second tranche of $400 million is available as a delayed draw term loan facility (DDTL) that Moderna can draw in multiple installments through November 2027 at management's discretion. A third $500 million DDTL tranche is available through November 2028, with draws contingent on Moderna achieving key regulatory milestones tied to its late-stage clinical pipeline, creating performance-based capital access aligned with development progress.
Jamey Mock, Moderna's Chief Financial Officer, stated that while the company remains positioned to achieve its 2028 cash breakeven target, the additional capital "enhances our strong balance sheet and enables increased flexibility over the coming years." The company has reiterated financial guidance provided during its third-quarter 2025 earnings call. Doug Dieter, Co-Head of Ares Specialty Healthcare, emphasized the strategic rationale, noting that "Moderna has already demonstrated the power of its mRNA platform with multiple commercial products and has an impressive and differentiated clinical pipeline."
The facility underscores institutional confidence in Moderna's business model and pipeline maturation. By securing non-dilutive debt rather than equity financing, Moderna preserves shareholder value while extending its runway to cash breakeven. The conditional structure of the third tranche—tied to regulatory achievements—aligns lender interests with clinical execution risk, a common feature in healthcare alternative lending. Legal advisors Goodwin and Proskauer supported the transaction for Moderna and Ares respectively, reflecting the complexity of the credit arrangement.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.